Management and costs of treating lung cancer patients in a university hospital

PharmacoEconomics

Volumn 22, Issue 7, 2004, Pages 435-444

  Dedes, Konstantin J ^a   Szucs, Thomas D ^b   Bodis, Stephan ^a   Joerger, Markus ^a   Lowy, Adam ^c   Russi, Erich W ^a   Steinert, Hans C ^a   Weder, Walter ^a   Stahel, Rolf A ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b CMO Hirslanden Holding   (Switzerland)

^c Swiss Inst for Appl Cancer Res   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MITOMYCIN; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TOPOTECAN; VINCRISTINE; VINDESINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HISTOPATHOLOGY; HOSPITAL COST; HOSPITALIZATION; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HEALTH RESOURCES; HOSPITAL COSTS; HOSPITALIZATION; HOSPITALS, UNIVERSITY; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PATIENT CARE TEAM; RETROSPECTIVE STUDIES;

EID: 2942603001     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200422070-00003     Document Type: Article

References (31)

1. Krebsbekämpfungsprogramm. Lungenkrebs: fakten und fandlungsbedarf. Bern: Bundesant für Geschdeit, 1997
2. Zangemeister-Wittke U, Stahel RA. Novel approaches to the treatment of small-cell lung cancer. Cell Mol Life Sci 1999; 55 (12): 1585-98
3. Swiss Society for Medical Oncology. Guidelines for treatment and follow-up of small cell lung cancer. Schweiz Aerztezeitung 1999; 80: 144
4. Swiss Society for Medical Oncology. Guidelines for treatment and follow-up of non-small cell lung cancer. Schweiz Aerztezeitung 1999; 80: 145
5. Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1NO), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002; 20 (1): 247-53
6. Weder W, Schmid RA, Bruchhaus H, et al. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg 1998; 66 (3): 886-92
7. Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000; 343 (4): 254-61
8. Dietlein M, Weber K, Gandjour A, et al. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results. Eur J Nucl Med 2000; 27 (11): 1598-609
9. Miles KA. An approach to demonstrating cost-effectiveness of diagnostic imaging modalities in Australia illustrated by positron emission tomography. Australas Radiol 2001; 45 (1): 9-18
10. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994; 330 (3): 153-8
11. Rosell R, Felip E. Role of multimodality treatment for lung cancer. Semin Surg Oncol 2000; 18 (2): 143-51
12. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311 (7010): 899-909
13. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990; 323 (14): 940-5
14. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer: adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997; 15 (8): 2996-3018
15. Paritätische Kommission. Spitalleistungskatalog. Bern: Paritätische Kommission, 1999
16. Finkler SA. The distinction between cost and charges. Ann Intern Med 1982; 96 (1): 102-9
17. Konkordat der Schweizerischen Krankenversicherer. Tagestaxen in heilanstalten. Bern: Konkordat der Schweizerischen Krankenversicherer, 1999
18. Szucs TD. The growing importance of cost-effectiveness in oncologic practice. Curr Opin Oncol 1998; 10 (4): 279-83
19. Smith TJ, Hillner BE, Desch CE. Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis. J Natl Cancer Inst 1993; 85 (18): 1460-74
20. Goodwin PJ, Shepherd FA. Economic issues in lung cancer: a review. J Clin Oncol 1998; 16 (12): 3900-12
21. Weissflog D, Matthys H, Hasse J, et al. Epidemiology and costs of lung cancer in Germany. Pneumologie 2001; 55 (7): 333-8
22. Riley GF, Potosky AL, Lubitz JD, et al. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995; 33 (8): 828-41
23. Wolstenholme JL, Whynes DK. The hospital costs of treating lung cancer in the United Kingdom. Br J Cancer 1999; 80 (1-2): 215-8
24. Oliver E, Killen J, Kiebert G, et al. Treatment pathways, resource use and costs in the management of small cell lung cancer. Thorax 2001; 56 (10): 785-90
25. Billingham LJ, Bathers S, Burton A, et al. Patterns, costs and cost-effectiveness of care in a trial of chemotherapy for advanced non-small cell lung cancer. Lung Cancer 2002; 37 (2): 219-25
26. Evans WK, Will BP, Berthelot JM, et al. The cost of managing lung cancer in Canada. Oncology (Huntingt) 1995; 9 (11 Suppl.): 147-53
27. Rosenthal MA, Webster PJ, Gebski VJ, et al. The cost of treating small cell lung cancer. Med J Aust 1992; 156 (9): 605-10
28. Levi F, Randimbison L, Te VC, et al. Trends in survival for patients diagnosed with cancer in Vaud, Switzerland, between 1974 and 1993. Ann Oncol 2000; 11 (8): 957-63
29. Travis WD, Lubin J, Ries L, et al. United States lung carcinoma incidence trends: declining for most histologie types among males, increasing among females. Cancer 1996; 77 (12): 2464-70
30. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer 1995; 75 (1 Suppl.): 191-202
31. Levi F, Franceschi S, La Vecchia C, et al. Lung carcinoma trends by histologic type in Vaud and Neuchatel, Switzerland, 1974-1994. Cancer 1997; 79 (5): 906-14